Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 4/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 4/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | SHBG | P04278 | 2/20 | 0.70 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.70 |
| ▸ | AR | P10275 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | MGAM | O43451 | 1/20 | 0.70 |
| ▸ | GABRP | O00591 | 4/20 | 0.63 |
| ▸ | GABRD | O14764 | 4/20 | 0.63 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.63 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.63 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.63 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.63 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18373741 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL13487248 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL19156379 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL14007476 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL12242383 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL37778 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL23699767 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL17776486 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL12646116 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG | |
| SCHEMBL13988206 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1GPBAR1CYP3A4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226189-A1 | MICROBIOME MICROORGANISM AND USES THEREOF | BIOMICA LTD. (IL) | 2024-07-11 | — | — | US | claimed |
| EP-4337234-A1 | MICROBIOME MICROORGANISM AND USES THEREOF | Biomica Ltd. (IL) | 2024-03-20 | — | — | EP | claimed |
| WO-2022239013-A1 | MICROBIOME MICROORGANISM AND USES THEREOF | BIOMICA LTD. (IL) | 2022-11-17 | — | — | WO | claimed |
| US-20210059920-A1 | Minoxidil Adjuvant Therapies | JUPITER WELLNESS INC. | 2021-03-04 | — | — | US | claimed |
| US-20180340005-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | DUKE UNIVERSITY | 2018-11-29 | — | — | US | claimed |
| US-10040816-B2 | Antagonists of CB1 receptor | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-08-07 | — | — | US | claimed |
| US-20140308350-A1 | NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | ALFA WASSERMANN S.P.A. (IT) | 2014-10-16 | — | — | US | claimed |
| US-20130245253-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | DEPARTMENT OF VETERANS AFFAIRS (US) | 2013-09-19 | — | — | US | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| US-20020152479-A1 | Car modulators: screening and treatment of hypercholesterolemia | ARROW ACQUISITION, LLC | 2002-10-17 | — | — | US | claimed |
| WO-2001051045-A2 | MODULATORS OF THE CONSTITUTIVE ADROSTANE RECEPTOR (CAR): SCREENING AND TREATMENT OF HYPERCHOLESTEROLEMIA | TULARIK INC. (US) | 2001-07-19 | — | — | WO | claimed |
| US-5439900-A | Synergistic mixture of steroid and alcohol | BUKUSOGLU CUNEYT (US) | 1995-08-08 | — | — | US | claimed |
| EP-0269786-B1 | Quantitative analysis of 3-oxo-5Beta-Steroid and reagent therefor | DAIICHI PURE CHEMICALS CO LTD (JP) | 1993-11-03 | — | — | EP | claimed |
| US-5085989-A | Contacting sample with specific dehydrogenase and tetrazolium salt, measuring optical density of colored substance produced; diagnosis of liver disorders | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1992-02-04 | — | — | US | claimed |
| JP-6001798-A | — | — | None | — | — | JP | disclosed |
| US-20250213591-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250186459-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250161325-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | SAGE THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4527461-A2 | A COMPOUND, COMPOSITIONS THEREOF AND THIS COMPOUND FOR USE IN METHODS OF TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250074935-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-03-06 | — | — | US | disclosed |
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-02-20 | — | — | US | disclosed |
| US-20250049719-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-02-13 | — | — | US | disclosed |
| EP-2806877-B2 | NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN | SAGE THERAPEUTICS INC (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-3885352-B1 | A COMPOUND, COMPOSITIONS THEREOF AND THIS COMPOUND FOR USE IN METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240368213-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4426712-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | Ripple Therapeutics Corporation (CA) | 2024-09-11 | — | — | EP | disclosed |
| US-12083131-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-12065463-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-12048706-B2 | Methods of treating epilepsy or status epilepticus | SAGE THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240226195-A1 | MICROBIAL CONSORTIUM AND USES THEREOF | BIOMICA LTD. (IL) | 2024-07-11 | — | — | US | disclosed |
| US-20240226189-A1 | MICROBIOME MICROORGANISM AND USES THEREOF | BIOMICA LTD. (IL) | 2024-07-11 | — | — | US | disclosed |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240117436-A1 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET | MAGI EUREGIO SCS (IT) | 2024-04-11 | — | — | US | disclosed |
| CN-117820482-A | Antibody of antiprogestin-progesterone antibody complex, and preparation method and application thereof | 杭州博茵生物技术有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11912738-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912738-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240009101-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20230416300-A1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4295908-A2 | NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN | Sage Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230404886-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| CN-117243839-A | Minoxidil adjuvant therapy | 应用生物学股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230355639-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230331768-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331768-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230322847-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322848-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322848-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322846-A9 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS INC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322846-A9 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS INC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322849-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322849-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322847-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116829922-A | Evaporation-based sample preparation workflow for mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11766392-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230265121-A9 | CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE | DUKE UNIVERSITY | 2023-08-24 | — | — | US | disclosed |
| US-20230225975-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-07-20 | — | — | US | disclosed |
| EP-4198133-A1 | GLYCOALKALOID METABOLISM ENYZYMES (GAMES) AND USES THEREOF | Yeda Research and Development Co. Ltd. (IL) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023086432-A1 | PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230149424-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230141665-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | disclosed |
| US-11628132-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230113666-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4146664-A2 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Ripple Therapeutics Corporation (CA) | 2023-03-15 | — | — | EP | disclosed |
| US-20230046825-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11554125-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-11542297-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542297-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3580343-B1 | GLYCOALKALOID METABOLISM ENYZYMES (GAMES) AND USES THEREOF | YEDA RES & DEV (IL) | 2022-12-28 | — | — | EP | disclosed |
| EP-4105223-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11530237-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530237-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4100017-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PureTech LYT, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11479802-B2 | Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family | REGENERON PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220288277-A1 | SURFACE COATINGS AND IMPLANTABLE DEVICES COMPRISING DIMERIC STEROID PRODRUGS, AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-09-15 | — | — | US | disclosed |
| US-20220289787-A1 | DIMER COMBINATIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-09-15 | — | — | US | disclosed |
| US-11426417-B2 | Neuroactive steroid formulations and methods of treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220213137-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220213137-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| EP-4009982-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | Marinus Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-4003362-A1 | ARTICLES COMPRISING STEROID DIMERS AND THEIR USE IN THE DELIVERY OF THERAPEUTIC AGENTS | Ripple Therapeutics Corporation (CA) | 2022-06-01 | — | — | EP | disclosed |
| US-20220153776-A1 | ANTAGONISTS OF CB1 RECEPTOR | INST NAT SANTE RECH MED (FR) | 2022-05-19 | — | — | US | disclosed |
| US-20220152050-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | SAGE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3996764-A1 | SURFACE COATINGS AND IMPLANTABLE DEVICES COMPRISING DIMERIC STEROID PRODRUGS, AND USES THEREOF | Ripple Therapeutics Corporation (CA) | 2022-05-18 | — | — | EP | disclosed |
| US-20220106351-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-04-07 | — | — | US | disclosed |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-03-22 | — | — | US | disclosed |
| WO-2022040545-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3957309-A1 | PREPARATION OF A COMPOSITION COMPRISING ALLOPREGNANOLONE AND SULFOBUTYLETHER-BETA-CYCLODEXTRIN | Sage Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220023313-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024968-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3911751-A1 | LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | Synpromics Ltd. (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-11-11 | — | — | US | disclosed |
| CN-113616661-A | Neuroactive steroids, compositions and uses thereof | 萨奇治疗股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| WO-2021220061-A2 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-11-04 | — | — | WO | disclosed |
| US-11147877-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11111266-B2 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| CN-113181112-A | Neuroactive steroid solutions and methods of their use | 萨奇治疗股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210113590-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20210113457-A1 | GLASS FORMULATIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-04-22 | — | — | US | disclosed |
| US-20210077444-A1 | Methods of Inducing Metabolic Maturation of Human Pluripotent Stem Cells-Derived Hepatocytes | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-03-18 | — | — | US | disclosed |
| CN-112472814-A | Neuroactive steroid formulations and methods of treating central nervous system disorders | 萨奇治疗股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10940156-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20210059920-A1 | Minoxidil Adjuvant Therapies | JUPITER WELLNESS INC. | 2021-03-04 | — | — | US | disclosed |
| WO-2021014217-A1 | ARTICLES COMPRISING STEROID DIMERS AND THEIR USE IN THE DELIVERY OF THERAPEUTIC AGENTS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-01-28 | — | — | WO | disclosed |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2021-01-21 | — | — | US | disclosed |
| WO-2021005417-A1 | SURFACE COATINGS AND IMPLANTABLE DEVICES COMPRISING DIMERIC STEROID PRODRUGS, AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATIONS (CA) | 2021-01-14 | — | — | WO | disclosed |
| EP-3400050-B1 | DRUG RELEASE DEVICE AND USE | JUROX PTY LTD (AU) | 2020-12-23 | — | — | EP | disclosed |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| EP-3740494-A1 | GLASS FORMULATIONS COMPRISING STEROID DIMERS AND USES THEREOF | Ripple Therapeutics Corporation (CA) | 2020-11-25 | — | — | EP | disclosed |
| US-20200306265-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10772863-B2 | Methods of inducing metabolic maturation of human pluripotent stem cells— derived hepatocytes | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2020-09-15 | — | — | US | disclosed |
| US-10774108-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-2983647-B1 | NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | ALFASIGMA SPA (IT) | 2020-09-09 | — | — | EP | disclosed |
| CN-111529537-A | Methods of treating epilepsy or status epilepticus | 萨奇治疗股份有限公司 | 2020-08-14 | — | — | CN | disclosed |
| US-20200253985-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200246459-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2020148555-A1 | LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | SYNPROMICS LIMITED (GB) | 2020-07-23 | — | — | WO | disclosed |
| US-10716795-B2 | Steroid analogues for neuroprotection | EMORY UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20200214958-A1 | Minoxidil Adjuvant Therapies | JUPITER WELLNESS INC. | 2020-07-09 | — | — | US | disclosed |
| EP-3170501-B1 | ANTAGONISTS OF CB1 RECEPTOR | INST NAT SANTE RECH MED (FR) | 2020-07-08 | — | — | EP | disclosed |
| WO-2020132504-A1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020118060-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20200171049-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-3650027-A1 | NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN | Sage Therapeutics, Inc. (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10632075-B2 | Glass formulations and uses thereof | RIPPLE THERAPEUTICS CORPORATION (CA) | 2020-04-28 | — | — | US | disclosed |
| US-20200123195-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3610029-A1 | ASSAYS FOR SCREENING ACTIVITY OF MODULATORS OF MEMBERS OF THE HYDROXYSTEROID (17-BETA) DEHYDROGENASE (HSD17B) FAMILY | Regeneron Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | disclosed |
| US-20190350944-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2019-11-21 | — | — | US | disclosed |
| EP-2806877-B1 | NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN | SAGE THERAPEUTICS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10426837-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190290474-A1 | DRUG RELEASE DEVICE AND USE | JUROX PTY LTD (AU) | 2019-09-26 | — | — | US | disclosed |
| US-20190275167-A1 | GLASS FORMULATIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2019-09-12 | — | — | US | disclosed |
| US-20190269699-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | SAGE THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20190247402-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| WO-2019148293-A1 | GLASS FORMULATIONS COMPRISING STEROID DIMERS AND USES THEREOF | INTERFACE BIOLOGICS, INC. (CA) | 2019-08-08 | — | — | WO | disclosed |
| US-10322139-B2 | Neuroactive steroid formulations and methods of treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190177358-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190071465-A1 | ANTAGONISTS OF CB1 RECEPTOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-07 | — | — | US | disclosed |
| US-20190038639-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | SAGE THERAPEUTICS INC (US) | 2019-02-07 | — | — | US | disclosed |
| EP-3426257-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20190008873-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS INC (US) | 2019-01-10 | — | — | US | disclosed |
| US-10150793-B2 | Antagonists of CB1 receptor | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-12-11 | — | — | US | disclosed |
| US-20180340005-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | DUKE UNIVERSITY | 2018-11-29 | — | — | US | disclosed |
| WO-2018169798-A9 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018190970-A1 | ASSAYS FOR SCREENING ACTIVITY OF MODULATORS OF MEMBERS OF THE HYDROXYSTEROID (17-BETA) DEHYDROGENASE (HSD17B) FAMILY | REGENERON PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20180291422-A1 | Assays For Screening Activity Of Modulators Of Members Of The Hydroxysteroid (17-Beta) Dehydrogenase (HSD17B) Family | REGENERON PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| WO-2018169798-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180221390-A1 | Steroid Analogues for Neuroprotection | UNIV EMORY (US) | 2018-08-09 | — | — | US | disclosed |
| US-10040816-B2 | Antagonists of CB1 receptor | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-08-07 | — | — | US | disclosed |
| WO-2018075698-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-3310394-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | Sage Therapeutics, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170348326-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348327-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170342102-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342102-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170319695-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170319695-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170266145-A1 | METHODS OF INDUCING METABOLIC MATURATION OF HUMAN PLURIPOTENT STEM CELLS-DERIVED HEPATOCYTES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-09-21 | — | — | US | disclosed |
| WO-2017156103-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170240589-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| EP-2709631-B9 | ANTAGONISTS OF CB1 RECEPTOR | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-3191101-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3170501-A1 | ANTAGONISTS OF CB1 RECEPTOR | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-05-24 | — | — | EP | disclosed |
| US-20170065615-A1 | Steroid Analogues for Neuroprotection | UNIV EMORY (US) | 2017-03-09 | — | — | US | disclosed |
| EP-2709631-B1 | ANTAGONISTS OF CB1 RECEPTOR | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-01-11 | — | — | EP | disclosed |
| US-9527881-B2 | Steroid analogues for neuroprotection | EMORY UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2016205721-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016164763-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016123056-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016082789-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20160145294-A1 | Antagonists of CB1 Receptor | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-05-26 | — | — | US | disclosed |
| WO-2016061527-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2016-04-21 | — | — | WO | disclosed |
| WO-2016040322-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| WO-2015161078-A1 | METHODS FOR COMPREHENSIVE PROFILING OF STEROID METABOLOME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2887944-A2 | METHODS OF TREATING EPILEPSY OR TATUS EPILEPTICUS | Sage Therapeutics, Inc. (US) | 2015-07-01 | — | — | EP | disclosed |
| CN-104736158-A | Neuroactive steroid formulations and methods of treating central nervous system disorders | SAGE THERAPEUTICS INC | 2015-06-24 | — | — | CN | disclosed |
| CN-104736159-A | Methods of treating epilepsy or status epilepticus | SAGE THERAPEUTICS INC | 2015-06-24 | — | — | CN | disclosed |
| EP-2806877-A2 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-20140308350-A1 | NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | ALFA WASSERMANN S.P.A. (IT) | 2014-10-16 | — | — | US | disclosed |
| US-8849577-B2 | Methods of identifying biochemical pathways | METABOLON, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014123909-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20140057885-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | SAGE THERAPEUTICS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031792-A2 | METHODS OF TREATING EPILEPSY OR TATUS EPILEPTICUS | SAGE THERAPEUTICS (US) | 2014-02-27 | — | — | WO | disclosed |
| US-8614203-B2 | Methods for the treatment of a central nervous system injury via a tapered administration protocol | EMORY UNIVERSITY (US) | 2013-12-24 | — | — | US | disclosed |
| US-8575376-B2 | Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them | USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CESKE REPUBLIKY, V.V.I. (CZ) | 2013-11-05 | — | — | US | disclosed |
| US-20130245253-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | DEPARTMENT OF VETERANS AFFAIRS (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013112605-A2 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| EP-2431042-B1 | Methods for the treatment of central nervous system injury via a tapered administration protocol | UNIV EMORY (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20120309728-A1 | NEW STEROID INHIBITORS OF PGP FOR USE FOR INHIBITING MULTIDRUG RESISTANCE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-12-06 | — | — | US | disclosed |
| US-20120289491-A1 | METHODS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | EMORY UNIVERSITY | 2012-11-15 | — | — | US | disclosed |
| US-20120283412-A1 | ORPHAN NUCLEAR RECEPTOR | KLIEWER STEVEN A (US) | 2012-11-08 | — | — | US | disclosed |
| US-8221991-B2 | Orphan nuclear receptor | GLAXOSMITHKLINE LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CEVC GREGOR (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20120071453-A1 | STEROIDE ANIONIC COMPOUNDS, METHOD OF THEIR PRODUCTION, USAGE AND PHARMACEUTICAL PREPARATION INVOLVING THEM | PSYCHIATRICKE CENTRUM PRAHA (CZ) | 2012-03-22 | — | — | US | disclosed |
| EP-2431042-A1 | Methods for the treatment of central nervous system injury via a tapered administration protocol | Emory University (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110306579-A1 | METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D | EMORY UNIVERSITY (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110275584-A1 | PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS | ONEPHARM RESEARCH AND DEVELOPMENT GMBH (AT) | 2011-11-10 | — | — | US | disclosed |
| US-20110263553-A1 | STEROID ANALOGUES FOR NEUROPROTECTION | EMORY UNIVERISITY | 2011-10-27 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110059478-A1 | Orphan Nuclear Receptor | GLAXOSMITHKLINE LLC | 2011-03-10 | — | — | US | disclosed |
| EP-2260052-A2 | STEROID ANALOGUES FOR NEUROPROTECTION | Emory University (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010088409-A2 | METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100092463-A1 | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-04-15 | — | — | US | disclosed |
| US-20100087413-A1 | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss | ONEPHARM RESEARCH AND DEVELOPMENT GMBH (AT) | 2010-04-08 | — | — | US | disclosed |
| EP-0701444-B1 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | PURDUE PHARMA LTD (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100061976-A1 | Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-03-11 | — | — | US | disclosed |
| US-20100035855-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-11 | — | — | US | disclosed |
| US-20100022494-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022488-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022489-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022487-A1 | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100023344-A1 | System and device for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022991-A1 | System and device for maintaining physiological levels of steroid hormone in a subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| US-20100022497-A1 | Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-01-28 | — | — | US | disclosed |
| WO-2009108804-A2 | STEROID ANALOGUES FOR NEUROPROTECTION | EMORY UNIVERSITY (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090221544-A1 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | EMORY UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090155235-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7528133-B1 | Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-05-05 | — | — | US | disclosed |
| EP-2036548-A1 | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss | onepharm Research & Development GmbH (AT) | 2009-03-18 | — | — | EP | disclosed |
| EP-1663185-B1 | PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS | ONEPHARM RES & DEV GMBH (AT) | 2008-12-10 | — | — | EP | disclosed |
| US-20080227764-A1 | USE OF PREGNANE-DIONES OR DIOLS AS NEUROPATHIC ANALGESIC AGENTS | PARAMOUNT BIOSCIENCES, LLC | 2008-09-18 | — | — | US | disclosed |
| US-20080171729-A1 | Use Of A Steroid For Enhancement Of Skin Permeability | NOVARTIS AG | 2008-07-17 | — | — | US | disclosed |
| US-20080161228-A1 | Using metabolomics to expedite drug discovery and development; invention provides means to select and advance most selective lead compounds from series of candidates based on metabolomic profiles which contain data regarding both expected or intended (e.g., on-target) and unexpected effects of compounds | METABOLON INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033575-A9 | METHODS OF IDENTIFYING BIOCHEMICAL PATHWAYS | METABOLON INC (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080096239-A1 | Orphan Nuclear Receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008033575-A2 | METHODS OF IDENTIFYING BIOCHEMICAL PATHWAYS | METABOLON, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1871382-A2 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION OF PROGESTERONE | Emory University (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1551370-B1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1038880-B1 | Androstanes and pregnanes for allosteric modulation of GABA receptor | EURO CELTIQUE SA (LU) | 2007-10-17 | — | — | EP | disclosed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| US-7238491-B1 | Pregnane X receptor method | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1773336-A1 | USE OF A STEROID FOR ENHANCEMENT OF SKIN PERMEABILITY | Novartis AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CEVC GREGOR | 2007-02-08 | — | — | US | disclosed |
| WO-2006102644-A9 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION OF PROGESTERONE | UNIV EMORY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060228778-A1 | Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof | PFIZER INC | 2006-10-12 | — | — | US | disclosed |
| US-7118885-B2 | Nucleic acid encoding vitamin D receptor related polypeptide | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| WO-2006101950-A2 | PXR AGONISTS FOR CARDIOVASCULAR DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102644-A2 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION OF PROGESTERONE | EMORY UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060211632-A1 | PXR agonists for cardiovascular disease | TOLEDO, UNIVERSITY OF, THE | 2006-09-21 | — | — | US | disclosed |
| EP-1663185-A1 | PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS | Bionetworks GmbH (DE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006048576-A1 | METHOD FOR PREPARING SPECIFIC AFFINITY ANTI-PROGESTERONE ANTIBODIES, THE OBTAINED ANTIBODIES AND THE USE THEREOF FOR IN VITRO DIAGNOSIS | BIOMERIEUX (FR) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006008092-A1 | USE OF A STEROID FOR ENHANCEMENT OF SKIN PERMEABILITY | NOVARTIS AG (CH) | 2006-01-26 | — | — | WO | disclosed |
| US-20050187188-A1 | Methods for the treatment of a traumatic central nervous system injury | EMORY UNIVERSITY (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2005027882-A1 | PREVENTION AND TREATMENT OF INFLAMMATION-INDUCED AND/OR IMMUNE-MEDIATED BONE LOSS | BIONETWORKS GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| EP-1244617-B1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | ORTHO MCNEIL PHARM INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050009796-A1 | Use of pregnane-diones or diols as neuropathic analgesic agents | MONASH UNIVERSITY (AU) | 2005-01-13 | — | — | US | disclosed |
| US-20040161794-A1 | Biosynthesis of HIF | THE GENERAL HOSPITAL CORPORATION | 2004-08-19 | — | — | US | disclosed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| US-20040092505-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | COATS STEVEN J (US) | 2004-05-13 | — | — | US | disclosed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | disclosed |
| EP-1365752-A2 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY WITH E.G. ALLOPREGNANOLONE | Emory University (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003087140-A1 | NON-PRIMATE FXRb AS A LANOSTEROL SENSING NUCLEAR HORMONE RECEPTOR AND RELATED USES | LION BIOSCIENCE AG (DE) | 2003-10-23 | — | — | WO | disclosed |
| US-6583179-B2 | For therapy of uterine fibroids, endometriosis, polycystic ovarian disease, dysfunctional uterine bleeding, breast cancer and ovarian cancer; depletion of oocytes; spermatocyte depletion; for female and male contraception | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-24 | — | — | US | disclosed |
| US-6579686-B2 | Detecting modulators of clotrimazole binding; mix modulator, clotrimazole and receptor, determine amount of clotrimazole bound to receptor, reduction in clotrimazole binding indicate a modulator of binding activity | SMITHKLINE BEECHAM CORPORATION | 2003-06-17 | — | — | US | disclosed |
| WO-2002030409-A9 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY | UNIV EMORY (US) | 2003-05-01 | — | — | WO | disclosed |
| US-20030032790-A1 | NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND USES THEREOF | PFIZER INC. | 2003-02-13 | — | — | US | disclosed |
| CN-1391479-A | Tolerance-inducing drugs | BIONETWORKS GMBH (DE) | 2003-01-15 | — | — | CN | disclosed |
| WO-2002094769-A1 | SOLID REAGENT FOR SAMPLING AND DERIVATIZATION OF CARBONYL COMPOUNDS | SEQUANT AB (SE) | 2002-11-28 | — | — | WO | disclosed |
| US-20020152479-A1 | Car modulators: screening and treatment of hypercholesterolemia | ARROW ACQUISITION, LLC | 2002-10-17 | — | — | US | disclosed |
| EP-1244617-A1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002070697-A1 | MAMMALIAN NUCLEAR RECEPTOR L67 AND METHODS OF USE | LION BIOSCIENCE AG (DE) | 2002-09-12 | — | — | WO | disclosed |
| US-20020072509-A1 | Methods for the treatment of a traumatic central nervous system injury | EMORY UNIVERSITY | 2002-06-13 | — | — | US | disclosed |
| WO-2002042322-A2 | MAMMALIAN NUCLEAR RECEPTOR COFACTORS CF7 AND CF8 AND METHODS OF USE | LION BIOSCIENCE AG (DE) | 2002-05-30 | — | — | WO | disclosed |
| US-20020058654-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2002030409-A2 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY | EMORY UNIVERSITY (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002024728-A2 | MAMMALIAN NUCLEAR RECEPTOR COFACTOR CF6 AND METHODS OF USE | LION BIOSCIENCE AG (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002018420-A2 | COFACTORS OF THE PREGNANE X RECEPTOR AND METHODS OF USE | LION BIOSCIENCE AG (DE) | 2002-03-07 | — | — | WO | disclosed |
| US-20010055815-A1 | Constitutive androstane receptor | COLLINS JON L (US) | 2001-12-27 | — | — | US | disclosed |
| WO-2001071361-A2 | CONSTITUTIVE ANDROSTANE RECEPTOR | GLAXO GROUP LIMITED (GB) | 2001-09-27 | — | — | WO | disclosed |
| EP-1126844-A1 | USE OF THIAZOLIDINEDIONES DERIVATIVES FOR PREVENTING UTERINE CONTRACTIONS IN PREMATURE LABOUR OR LACTATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6277838-B1 | ADMINISTERING DOSAGE OF ANXIOLYTIC AGENT TO ANIMAL | COCENSYS, INC. | 2001-08-21 | — | — | US | disclosed |
| WO-2001051045-A2 | MODULATORS OF THE CONSTITUTIVE ADROSTANE RECEPTOR (CAR): SCREENING AND TREATMENT OF HYPERCHOLESTEROLEMIA | TULARIK INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001047875-A1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-07-05 | — | — | WO | disclosed |
| US-6245757-B1 | REDUCING DAMAGE DUE TO STROKE OR MYCARDIUM INFARCTION; CENTRAL NERVOUS SYSTEM AND CARDIOVASCULAR DISORDERS | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2001-06-12 | — | — | US | disclosed |
| EP-0808325-B1 | ANDROSTANE AND PREGNANE SERIES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS INC (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6143736-A | USED TO ALLEVIATE STRESS, ANXIETY, SEIZURES, MOOD DISORDERS, PREMENSTRUAL SYNDROME(PMS) AND POSTNATAL DEPRESSION (PND AND TO INDUCE ANESTHESIA | COCENSYS, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-1038880-A2 | Androstanes and pregnanes for allosteric modulation of GABA receptor | COCENSYS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-0752860-B1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | EURO CELTIQUE SA (LU) | 2000-08-23 | — | — | EP | disclosed |
| EP-1023323-A1 | NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND USES THEREOF | Pharmacia & Upjohn Aktiebolag (SE) | 2000-08-02 | — | — | EP | disclosed |
| WO-2000025781-A1 | USE OF THIAZOLIDINEDIONES DERIVATIVES FOR PREVENTING UTERINE CONTRACTIONS IN PREMATURE LABOUR OR LACTATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999019354-A9 | NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND USES THEREOF | PHARMACIA & UPJOHN AB (SE) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999048915-A9 | ORPHAN NUCLEAR RECEPTOR | GLAXO GROUP LTD (GB) | 1999-11-18 | — | — | WO | disclosed |
| US-5939545-A | MODULATING THE GABA.SUB.A (GAMMA-AMINOBUTYRIC ACID A) RECEPTOR-CHLORIDE IONOPHORE COMPLEX TO ALLEVIATE STRESS, ANXIETY, SEIZURES, MOOD DISORDERS, PMS (PREMENSTRUAL SYNDROME) AND PND (POSTNATAL DEPRESSION) AND TO INDUCE ANESTHESIA | COCENSYS, INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999019354-A1 | NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND USES THEREOF | PHARMACIA & UPJOHN AB (SE) | 1999-04-22 | — | — | WO | disclosed |
| EP-0808325-A4 | — | — | 1997-12-17 | — | — | EP | disclosed |
| EP-0808325-A1 | ANDROSTANE AND PREGNANE SERIES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5567830-A | Process for synthesis of acetylenic carbinols | COCENSYS, INC. (US) | 1996-10-22 | — | — | US | disclosed |
| WO-1996016076-A1 | ANDROSTANE AND PREGNANE SERIES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1995021617-A1 | ANDROSTANES AND PREGNANES FOR ALLOSTERIC MODULATION OF GABA RECEPTOR | COCENSYS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5439900-A | Synergistic mixture of steroid and alcohol | BUKUSOGLU CUNEYT (US) | 1995-08-08 | — | — | US | disclosed |
| JP-H061798-A | PRODUCTION OF CARDIAC GLYCOSIDE | P C C TECHNOL:KK | 1994-01-11 | — | — | JP | disclosed |
| EP-0269786-B1 | Quantitative analysis of 3-oxo-5Beta-Steroid and reagent therefor | DAIICHI PURE CHEMICALS CO LTD (JP) | 1993-11-03 | — | — | EP | disclosed |
| US-5085989-A | Contacting sample with specific dehydrogenase and tetrazolium salt, measuring optical density of colored substance produced; diagnosis of liver disorders | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0269786-A1 | Quantitative analysis of 3-oxo-5Beta-Steroid and reagent therefor | DAIICHI PURE CHEMICALS CO. LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| US-4102884-A | TREATING A 3,14-DIHYDROXY-CARDENOLIDE WITH OXYGEN AND N-BROMOACETAMIDE IN THE PRESENCE OF PLATINUM, THEN WITH ETHANEDITHIOL, RANEY NICKEL | STEELE CHEMICALS CO. LTD. (CA) | 1978-07-25 | — | — | US | disclosed |
| US-4102884-A | TREATING A 3,14-DIHYDROXY-CARDENOLIDE WITH OXYGEN AND N-BROMOACETAMIDE IN THE PRESENCE OF PLATINUM, THEN WITH ETHANEDITHIOL, RANEY NICKEL | STEELE CHEMICALS CO. LTD. (CA) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071453-A1 | STEROIDE ANIONIC COMPOUNDS, METHOD OF THEIR PRODUCTION, USAGE AND PHARMACEUTICAL PREPARATION INVOLVING THEM | GRIN2A, GRIN2B, GRIN1 | AKR1B10 1578/4885AKR1B1 1311/4885GPBAR1 261/4885 |
| US-20250213591-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | GAP43, HSD3B1, CYP17A1 | AKR1B10 419/4885AKR1B1 451/4885GPBAR1 1244/4885 |
| US-20090221544-A1 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | CYP21A2, BDNF, CYP17A1 | AKR1B10 537/4885AKR1B1 238/4885GPBAR1 1298/4885 |
| US-20230322849-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | AKR1B10 666/4885AKR1B1 528/4885GPBAR1 326/4885 |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | AKR1B10 298/4885AKR1B1 189/4885GPBAR1 241/4885 |
| US-20220106351-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CRYAB, UACA, CRYAA | AKR1B10 2060/4885AKR1B1 1423/4885GPBAR1 673/4885 |
| US-20110306579-A1 | METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D | CYP27B1, GAP43, VDR | AKR1B10 2071/4885AKR1B1 1336/4885GPBAR1 2662/4885 |
| US-20230149424-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | NR3C2, NR3C1, HSD3B1 | AKR1B10 814/4885AKR1B1 655/4885GPBAR1 815/4885 |
| US-20220289787-A1 | DIMER COMBINATIONS AND USES THEREOF | SHBG, SERPINA6, FKBP2 | AKR1B10 1366/4885AKR1B1 1850/4885GPBAR1 2193/4885 |
| US-20230355639-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | GAP43, CYP17A1, HSD3B1 | AKR1B10 401/4885AKR1B1 443/4885GPBAR1 913/4885 |
| US-20020058654-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | FSHR, GNRHR, SHBG | AKR1B10 525/4885AKR1B1 670/4885GPBAR1 336/4885 |
| US-20250074935-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CRYAB, UACA, CRYAA | AKR1B10 2060/4885AKR1B1 1423/4885GPBAR1 673/4885 |
| US-20190177358-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | AKR1B10 369/4885AKR1B1 277/4885GPBAR1 172/4885 |
| US-20120309728-A1 | NEW STEROID INHIBITORS OF PGP FOR USE FOR INHIBITING MULTIDRUG RESISTANCE | ABCC1, ABCB1, ABCB11 | AKR1B10 351/4885AKR1B1 170/4885GPBAR1 73/4885 |
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | GABRA4, GABRG1, GABRB2 | AKR1B10 1052/4885AKR1B1 651/4885GPBAR1 185/4885 |
| US-20080096239-A1 | Orphan Nuclear Receptor | NR1H4, NR1H3, NR1H2 | AKR1B10 268/4885AKR1B1 126/4885GPBAR1 74/4885 |
| US-20020152479-A1 | Car modulators: screening and treatment of hypercholesterolemia | LDLR, LCAT, CETP | AKR1B10 1250/4885AKR1B1 968/4885GPBAR1 40/4885 |
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | CCND2, CCND1, C9 | AKR1B10 1459/4885AKR1B1 1026/4885GPBAR1 1341/4885 |
| US-20190275167-A1 | GLASS FORMULATIONS AND USES THEREOF | GBA2, AGER, GBA1 | AKR1B10 1260/4885AKR1B1 1241/4885GPBAR1 271/4885 |
| US-11530237-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | AKR1B10 369/4885AKR1B1 277/4885GPBAR1 172/4885 |
| US-20210113457-A1 | GLASS FORMULATIONS AND USES THEREOF | GBA2, AGER, GBA1 | AKR1B10 1260/4885AKR1B1 1241/4885GPBAR1 271/4885 |
| US-10577390-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, GRIN2B | AKR1B10 428/4885AKR1B1 317/4885GPBAR1 172/4885 |
| US-20220220150-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | AKR1B10 370/4885AKR1B1 277/4885GPBAR1 170/4885 |
| US-20110263553-A1 | STEROID ANALOGUES FOR NEUROPROTECTION | CYP11A1, NR3C2, HSD17B7 | AKR1B10 283/4885AKR1B1 285/4885GPBAR1 823/4885 |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | AKR1B10 353/4885AKR1B1 257/4885GPBAR1 215/4885 |
| US-20250049719-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | NR3C1, NR3C2, CYP21A2 | AKR1B10 1361/4885AKR1B1 830/4885GPBAR1 1601/4885 |
| US-20180221390-A1 | Steroid Analogues for Neuroprotection | CYP11A1, NR3C2, HSD17B7 | AKR1B10 283/4885AKR1B1 285/4885GPBAR1 823/4885 |
| US-20200171049-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | GAP43, CYP17A1, HSD3B1 | AKR1B10 401/4885AKR1B1 443/4885GPBAR1 913/4885 |
| US-20250186459-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | NR3C2, NR3C1, HSD3B1 | AKR1B10 814/4885AKR1B1 655/4885GPBAR1 815/4885 |
| US-20130245253-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | SHBG, TACR2, GAP43 | AKR1B10 706/4885AKR1B1 517/4885GPBAR1 369/4885 |
| US-20170319695-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SLC6A1, CNR1, MC2R | AKR1B10 309/4885AKR1B1 216/4885GPBAR1 177/4885 |
| US-20070031483-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | AKR1B10 1836/4885AKR1B1 2658/4885GPBAR1 1764/4885 |
| US-20230331768-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | AKR1B10 68/4885AKR1B1 47/4885GPBAR1 88/4885 |
| US-20120177698-A1 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | CUTA, ABCG2, ABCB11 | AKR1B10 2236/4885AKR1B1 2948/4885GPBAR1 1774/4885 |
| US-10632075-B2 | Glass formulations and uses thereof | GBA2, AGER, GBA1 | AKR1B10 1260/4885AKR1B1 1241/4885GPBAR1 271/4885 |
| US-20190350944-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SHBG, CRH, NR3C2 | AKR1B10 1065/4885AKR1B1 1253/4885GPBAR1 394/4885 |
| US-20080227764-A1 | USE OF PREGNANE-DIONES OR DIOLS AS NEUROPATHIC ANALGESIC AGENTS | OPRL1, OPRK1, OPRD1 | AKR1B10 559/4885AKR1B1 414/4885GPBAR1 50/4885 |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | CRYAB, UACA, CRYAA | AKR1B10 2060/4885AKR1B1 1423/4885GPBAR1 673/4885 |
| US-20220152050-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | GRIK4, GABRE, GRIK2 | AKR1B10 735/4885AKR1B1 666/4885GPBAR1 1052/4885 |
| US-20220024968-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | AKR1B10 69/4885AKR1B1 47/4885GPBAR1 92/4885 |
| US-20230265121-A9 | CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE | SHBG, TACR2, GAP43 | AKR1B10 706/4885AKR1B1 517/4885GPBAR1 369/4885 |
| US-11554125-B2 | Neuroactive steroids, compositions, and uses thereof | GAP43, CYP17A1, HSD3B1 | AKR1B10 401/4885AKR1B1 443/4885GPBAR1 913/4885 |
| US-20200392177-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | ADRA1B, ADRA2B, ADRA1A | AKR1B10 369/4885AKR1B1 277/4885GPBAR1 172/4885 |
| US-20180340005-A1 | Conjugated Neuroactive Steroid Compositions And Methods Of Use | SHBG, TACR2, GAP43 | AKR1B10 674/4885AKR1B1 518/4885GPBAR1 374/4885 |
| US-20120289491-A1 | METHODS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | CYP21A2, NR3C2, CYP11B2 | AKR1B10 565/4885AKR1B1 269/4885GPBAR1 1348/4885 |
| US-20230322847-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | AKR1B10 624/4885AKR1B1 463/4885GPBAR1 325/4885 |
| US-20210017218-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | AKR1B10 353/4885AKR1B1 257/4885GPBAR1 215/4885 |
| US-20220023313-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | GAP43, CYP17A1, HSD3B1 | AKR1B10 401/4885AKR1B1 443/4885GPBAR1 913/4885 |
| US-20150313913-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE GABA-A RECEPTOR IN THE TREATMENT OF AUTISM | GABRB2, GABRA4, GABRB1 | AKR1B10 3059/4885AKR1B1 3067/4885GPBAR1 487/4885 |
| US-11912738-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | AKR1B10 666/4885AKR1B1 528/4885GPBAR1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.